News

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Mirati Therapeutics, in collaboration with Array BioPharma (Pfizer) and Monoceros [...]

By Michael Jaramillo|2022-10-19T17:45:12+00:00October 10th, 2022|News|Comments Off

Monoceros Biosystems Recognized on Inc. 5000 List of Fastest-Growing Private Companies in America

By Michael Jaramillo|2022-08-22T15:21:57+00:00August 19th, 2022|News|Comments Off

Monoceros Biosystems has been selected as a top 10 bioinformatics solution provider for 2020 by the CIO Applications magazine

By Michael Jaramillo|2022-08-10T03:59:37+00:00August 18th, 2020|News|Comments Off

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Mirati Therapeutics, in collaboration with additional groups including Monoceros Biosystems, [...]

By Michael Jaramillo|2022-08-10T04:00:42+00:00January 1st, 2020|News|Comments Off

Monoceros Biosystems: Bringing Professional Grade Bioinformatics to All

Monoceros Biosystems has been selected as a top 10 bioinformatics [...]

By Michael Jaramillo|2022-08-10T04:00:12+00:00September 25th, 2019|News|Comments Off

Monoceros Biosystems, a top bioinformatics/computational biology industry partner, is pleased to announce the appointment of John Lamb, PhD and Dan Rawlins, JD to its Advisory Board

Monoceros Biosystems LLC is pleased to announce that John Lamb, [...]

By Michael Jaramillo|2022-08-09T23:21:36+00:00September 23rd, 2019|News|Comments Off